RESULTS OF THE MARS STUDY ON THE MANAGEMENT OF ANTIANGIOGENICS’ RENOVASCULAR SAFETY IN LUNG CANCER

Author(s): Goldwasser, F; Janus, N; Morere, JF; Ray-Coquard, I; Spano, JP; Gligorov J; Rey, JB; Daniel, C; Fabre, E; Launay-Vacher, V

Conference: 17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress on Reinforcing Multidisciplinarity

Location: Amsterdam, NETHERLANDS Date: SEP 27-OCT 01, 2013

Sponsor(s): ECCO; ESMO; ESTRO


DOES BUFFY COAT PREPARED FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN CANCER PATIENTS HAS PROCOAGULANT PROPERTIES? AN IN VITRO STUDY

Author(s): Sidibe, F; Vassiliki, G; Robert, F; Romain, MP; Bernaudin, JF; Lotz JP; Selle, F; Larghero, J; Hatmi, M; Van Dreden, P; Gerotziafas, G; Elalamy, I

Conference: 22nd International Congress on Thrombosis

Location: Nice, FRANCE Date: OCT 06-09, 2012

Source: THROMBOSIS RESEARCH Volume: 130 Supplement: 1 Pages: S166-S167 DOI: 10.1016/j.thromres.2012.08.172 Published: OCT 2012

THE TAXIF II PROTOCOL FINAL RESULTS: A PHASE II TRIAL OF HIGH-DOSE CHEMOTHERAPY SUPPORTED BY HAEematopoietic STEM CELL TRANSPLANTATION IN PATIENTS WITH DISSEMINATED GERM-CELL TUMORS FAILING CHEMOTHERAPY AND WITH ADVERSE PROGNOSTIC FACTORS

Author(s): Selle, F; Fizazi, K; Biron, P; Gravis-Mescam, G; Bui, B; Bay, J; Flechon, A; Caty, A; Burcoveanu, D; Delva, R; de Revel, T; Miclea, JM; Gautela, M; Horn, E; Provent, S; Temby, I; Brindel, I; Khalil, J; Gligorov, J; Lotz JP

37th Congress of the European-Society-for-Medical-Oncology (ESMO)

Location: Vienna, AUSTRIA Date: SEP 28-OCT 02, 2012

Sponsor(s): European Soc Med Oncol (ESMO)


EFFECT OF METASTASIS SURGERY ON OVERALL SURVIVAL IN PATIENTS (PTS) WITH ADVANCED SOFT TISSUE SARCOMA (ASTS): A SUBANALYSIS OF THE PALSAR TRIALS

Author(s): Kotecki, N; Nguyen, BB; Blay, JY; Mathoulin-Pelissier, S; Chevreau, C; Thariat, J; Cupissol, D; Bay, JO; Coindre, JM; Lotz JP; Jimenez, M; Broustel, V; Guillemet, C; Italiano, A; Penel, N

Conference: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Location: Chicago, IL Date: JUN 01-06, 2012

Sponsor(s): Amer Soc Clin Oncol (ASCO)

Source: JOURNAL OF CLINICAL ONCOLOGY Volume: 30 Issue: 15 Supplement: S Meeting Abstract: 10035 Published: MAY 20 2012

ROSIA: A SINGLE-ARM STUDY IN MORE THAN 1000 PATIENTS (PTS) RECEIVING FRONT-LINE BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) FOR OVARIAN CANCER (OC)

Author(s): Mendiola, C; Davidenko, I; Colombo, N; Korach, J; Selle F; Gocze, P; Chmielowska, E; Pautier, P; Bollag, D; Oza, AM

Conference: 37th Congress of the European-Society-for-Medical-Oncology (ESMO)

Location: Vienna, AUSTRIA Date: SEP 28-OCT 02, 2012

Sponsor(s): European Soc Med Oncol (ESMO)


FROM A WEBSITE TO A NATIONAL AND REGIONAL REFERENCE CENTRE NETWORK: THE FRENCH EXPERIENCE FOR RARE OVARIAN TUMORS
SAFETY OF FRONT-LINE BEVACIZUMAB (BEV) COMBINED WITH WEEKLY PACLITAXEL (WPAC) AND Q3W CARBOPLATIN (C) FOR OVARIAN CANCER (OC): RESULTS FROM OCTAVIA.

Author(s): Gonzalez-Martin, A ; Gladeiﬀ, L ; Tholander, B ; Stroyakovsky, D ; Gore, ME ; Segalla, JGM ; Reyners, AKL ; Kovalenko, N ; Oaknin, A ; Selle F ; Bollag, DT ; Pignata, S

Conference: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Location: Chicago, IL Date: JUN 01-06, 2012

Sponsor(s): Amer Soc Clin Oncol (ASCO)

Source: JOURNAL OF CLINICAL ONCOLOGY Volume: 30 Issue: 15 Supplement: S Meeting

Abstract: 5067 Published: MAY 20 2012

MANAGEMENT OF ANTIANGIOGENICS´ RENOVASCULAR SAFETY IN OVARIAN CANCER SUBGROUP AND INTERMEDIATE RESULTS OF THE MARS STUDY.

Author(s): Launay-Vacher, V ; Janus, N ; Gilgiorov, J ; Selle F ; Goldwasser, F ; Mir, O ; Spano, JP ; Thery, JC ; Beuzeboc, P ; Daniel, C ; Rey, JB ; Jouanaud, C ; Morere, JF ; Oudard, S ; Azizi, M ; Deray, G ; Ray-Coquard, I

Conference: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Location: Chicago, IL Date: JUN 01-06, 2012

Sponsor(s): Amer Soc Clin Oncol (ASCO)

Source: JOURNAL OF CLINICAL ONCOLOGY Volume: 30 Issue: 15 Supplement: S Meeting

Abstract: 5017 Published: MAY 20 2012

LENALIDOMIDE (REV) IN ASYMPTOMATIC LATE RECURRENT OVARIAN CANCER (ROC) PATIENTS WITH INCREASING CA 125: A GINECO PHASE II TRIAL

Author(s): Selle F ; Ray-Coquard, I ; Sevin, E ; Mari, V ; Berton-Rigaud, D ; Dohollou, N ; Fabbro, M ; Floquet, A ; Lesoin, A ; Lortholary, A ; Hardy-Bessard, AC ; Misset, JL ; Mouret-Reynier, MA ; Pujade-Lauraine, E

Conference: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Location: Chicago, IL Date: JUN 01-06, 2012

Sponsor(s): Amer Soc Clin Oncol (ASCO)

Source: JOURNAL OF CLINICAL ONCOLOGY Volume: 30 Issue: 15 Supplement: S Meeting

Abstract: 5018 Published: MAY 20 2012

META-ANALYSIS OF PROSPECTIVE EUROPEAN STUDIES ASSESSING THE IMPACT OF USING THE 21-GENE RECURRENT SCORE ASSAY ON CLINICAL DECISION MAKING IN WOMEN WITH ER-POSITIVE, HER2-NEGATIVE EARLY STAGE BREAST CANCER

Author(s): Albanell, J ; Holt, S ; Gligorov J ; Eiermann, W ; Svedman, C

Conference: 37th Congress of the European-Society-for-Medical-Oncology (ESMO)

Location: Vienna, AUSTRIA Date: SEP 28-OKT 02, 2012

Sponsor(s): European Soc Med Oncol (ESMO)


Times Cited: 0 (from Web of Science)

SAFEHER: A STUDY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB (H-SC) AS ADJUVANT THERAPY IN PATIENTS WITH EARLY HER2-POSITIVE BREAST CANCER (EBC)
BEVACIZUMAB-CAPECITABINE (BEV-CAP) AFTER INITIAL 1ST-LINE BEVACIZUMAB-DOCETAXEL (BEV-DOC) IN PATIENTS (PTS) WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC): SAFETY ANALYSIS OF THE IMELDA TRIAL
Author(s): Gligorov J ; Alba-Conejo, E ; Bines, J ; Cortes, PA ; Doval, DC ; Jiang, Z ; Freudensprung, U ; Mustacchi, G
Conference: 37th Congress of the European-Society-for-Medical-Oncology (ESMO)
Location: Vienna, AUSTRIA
Date: SEP 28- OCT 02, 2012

PROSPECTIVE STUDY OF THE IMPACT OF USING THE 21-GENE RECURRENT SCORE ASSAY ON CLINICAL DECISION MAKING IN WOMEN WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, EARLY-STAGE BREAST CANCER IN FRANCE.
Author(s): Gligorov J ; Pivot, XB ; Naman, HL ; Jacot, W ; Spaeth, D ; Misset, JL ; Largillier, R ; Sautiere, JL ; de Roquancourt, A ; Pomel, C ; Rouanet, P ; Rouzier, R ; Penault-Llorca, FM
Group Author(s): Francilian Breast Intergrp
Conference: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Location: Chicago, IL
Date: JUN 01-06, 2012

IMPACT OF BIOMARKERS IN PREDICTIVITY OF THE EFFICACY AND TOXICITY OF A COMBINATION OF PANITUMUMAB PLUS FEC 100 FOLLOWED BY DOCETAXEL IN A PHASE II NEOADJUVANT TRIAL FOR TRIPLE-NEGATIVE BREAST CANCER (TNBC) PATIENTS
Author(s): Nabholz, Jean-Marc A.; Dauplat, Marie-Melanie; Abrial, Catherine; Gligorov J et al.
Conference: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Location: Chicago, IL
Date: JUN 01-06, 2012
Source: JOURNAL OF CLINICAL ONCOLOGY Volume: 30 Issue: 15 Supplement: S Meeting Abstract: 1051 Published: MAY 20 2012

OUTCOME OF HER2-POSITIVE BREAST CANCER PATIENTS FOLLOWING METASTATIC RELAPSE AFTER ADJUVANT TRASTUZUMAB TREATMENT SINCE EMA REGULATORY APPROVAL.
Author(s): Spano, Jean-Philippe; Vignot, Stephane; Ho, Xuan Dung; Gligorov J et al.
Conference: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Location: Chicago, IL
Date: JUN 01-06, 2012

COST-EFFECTIVENESS EVALUATION OF THE 21-GENE BREAST CANCER TEST IN FRANCE
Author(s): Rouzier, R.; Chereau, E.; Laas, E.; Gligorov J et al.
Conference: 4th IMPAKT Breast Cancer Conference
Location: Brussels, BELGIUM
Date: MAY 03-05, 2012
PREFHER: A CLINICAL TRIAL TO EVALUATE PATIENT PREFERENCE FOR TRASTUZUMAB ADMINISTERED SUBCUTANEOUSLY OR INTRAVENOUSLY IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER
Author(s): Pivot, X.; Knoop, A.; Curigliano, G.; Gligorov J et al.
Conference: 8th European Breast Cancer Conference (EBCC)
Location: Vienna, AUSTRIA Date: MAR 21-24, 2012
Sponsor(s): European Canc Org (ECCO)
Source: EUROPEAN JOURNAL OF CANCER Volume: 48 Supplement: 1 Pages: S176-S176 Published: MAR 2011

HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL SUPPORT FOR THE HEAVILY PRETREATED PATIENTS WITH GERM CELL TUMOURS: A SERBIAN SINGLE-CENTRE FIRST-EXPERIENCE REPORT
Author(s): Popovic, L; Jovanovic, D; Donat, D; Petrovic, D; Roganovic, T; Lotz JP
Conference: 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group
Location: Paris, FRANCE Date: APR 03-06, 2011
Sponsor(s): European Grp Bone & Marrow Transplantat; European Grp Bone & Marrow Transplantat Nurses Grp; European Grp Bone & Marrow Transplantat Management Grp
Source: BONE MARROW TRANSPLANTATION Volume: 46 Supplement: 1 Pages: S385-S385 Published: APR 2011

EXPERIENCE WITH BEVACIZUMAB IN THE MANAGEMENT OF RELAPSED OVARIAN CANCER - A RETROSPECTIVE OBSERVATIONAL STUDY IN FIVE FRENCH HOSPITALS
Author(s): Dubot, C ; Emile, GA ; Lhomme, C ; Asmane, I ; Pautier, P ; Alexandre, J ; Goldwasser, F ; Lauraine, EP ; Coquard, IR ; Selle F
Conference: European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care
Location: Stockholm, SWEDEN Date: SEP 23-27, 2011
Source: EUROPEAN JOURNAL OF CANCER Volume: 47 Supplement: 1 Pages: S528-S528 Published: SEP 2011

CHEMOTHERAPY AND BEVACIZUMAB COMBINATIONS IN SECOND-LINE OR MORE FOR METASTATIC BREAST CANCER: EFFICACY AND TOXICITY RESULTS
Author(s): Fillette, A ; Guerin, C ; Debrix, I ; Selle, F ; Ontkova, M ; Beerblock, K ; Avenin, D ; Esteso, A ; Lotz JP ; Gligorov, J
Conference: European Breast Cancer Conference
Location: Barcelona, SPAIN Date: MAR 24-26, 2010
Source: EJC SUPPLEMENTS Volume: 8 Issue: 3 Pages: 203-203 DOI: 10.1016/S1359-6349(10)70513-9 Published: MAR 2010

IMPACT OF EPOETIN BETA ON EXECUTIVE FUNCTIONS IN ANAEMIC PATIENTS WITH BREAST CANCER RECEIVING CHEMOTHERAPY: RESULTS OF A PROSPECTIVE COHORT STUDY
Author(s): Pivot, X.; Hugonot-Diener, L.; Coscas, Y.; Gligorov J et al.
Conference: 35th European-Society-for-Medical-Oncology (ESMO)
Congress Location: Milan, ITALY Date: OCT 08-12, 2010
Sponsor(s): European Soc Med Oncol
Source: ANNALS OF ONCOLOGY Volume: 21 Supplement: 8 Pages: 396-396 Published: OCT 2010

PREGNANCY-ASSOCIATED BREAST CANCER IS AS CHEMOSENSITIVE AS CLASSIC BREAST CANCER IN THE NEOADJUVANT SETTING
JOINT DISORDERS FREQUENCY AND STRUCTURAL CHANGES DURING ANASTROZOLE ADJUVANT TREATMENT IN EARLY BREAST CANCER: A PROSPECTIVE TRIAL (D5392L00013)
Author(s): Delozier, T.; Daban, A.; Dieras, V; Gligorov J et al.
Conference: 32nd Annual San Antonio Breast Cancer Symposium
Location: San Antonio, TX Date: DEC 09-13, 2009
Source: CANCER RESEARCH Volume: 69 Issue: 24 Supplement: 3 Pages: 527S-527S Published: DEC 15 2009

ADDITION OF BIBW 2992, AN IRREVERSIBLE INHIBITOR OF EGFR/HER1 AND HER2 INHIBITOR, TO TREATMENT CONTINUATION OF LETROZOLE IN ESTROGEN RECEPTOR (ER-) POSITIVE METASTATIC BREAST CANCER PROGRESSING ON LETROZOLE
Author(s): Gunzer, K.; Joly, F.; Delozier, T.; Gligorov J et al.
Conference: 32nd Annual San Antonio Breast Cancer Symposium
Location: San Antonio, TX Date: DEC 09-13, 2009
Source: CANCER RESEARCH Volume: 69 Issue: 24 Supplement: 3 Pages: 739S-739S Published: DEC 15 2009

A VERY FAVOURABLE MAMMOGRAPHIC SCREENING IMPACT ON BREAST CANCER CHARACTERISTICS AND TREATMENT MODALITIES IN FRANCE. ANALYSIS OF 2806 CASES.
Author(s): Cutuli, B.; Dalenc, F.; Guastalla, J-P; Gligorov J et al.
Conference: 32nd Annual San Antonio Breast Cancer Symposium
Location: San Antonio, TX Date: DEC 09-13, 2009
Source: CANCER RESEARCH Volume: 69 Issue: 24 Supplement: 3 Pages: 708S-708S Published: DEC 15 2009

RENAL FUNCTION EVOLUTION IN CANCER PATIENTS RESULTS OF THE IRMA-2 STUDY
Author(s): Oudard, S.; Janus, N.; Gligorov J; et al.
Conference: 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology
Location: Berlin, GERMANY Date: SEP 20-24, 2009
Sponsor(s): European Canc Org; European Soc Med Oncol
Source: EJC SUPPLEMENTS Volume: 7 Issue: 2 Pages: 177-178 Published: SEP 2009

PREVALENCE AND MANAGEMENT OF OROPHARYNGEAL CANDIDIASIS IN CANCER PATIENTS: RESULTS OF A PROSPECTIVE FRENCH MULTICENTRIC SURVEY
Author(s): Azria, D.; Gligorov J
Conference: 45th Annual Meeting of the American-Society-of-Clinical-Oncology
Location: Orlando, FL Date: MAY 29-JUN 02, 2009
Sponsor(s): Amer Soc Clin Oncol

PREVALENCE OF RENAL INSUFFICIENCY IN CANCER PATIENTS: DATA FROM THE IRMA-2 STUDY
Author(s): Janus, N.; Oudard, S.; Beuzeboc, P.; Gligorov J et al.
Conference: 45th Annual Meeting of the American-Society-of-Clinical-Oncology
ADJUVANT ENDOCRINE TREATMENT OF BREAST CANCER
Author(s): Gligorov, J; Namer, M
Conference: Educational Cancer Convention (ECCLU)
Location: Lugano, SWITZERLAND Date: JUL 02-04, 2009
Sponsor(s): European Sch Oncol
Source: ANNALS OF ONCOLOGY Volume: 20 Pages: 73-73 Published: SEP 2008

FRENCH EXPERIENCE OF PATIENTS’ MANAGEMENT WHEN RECEIVING VINORELBINE ORAL CHEMOTHERAPY (NVBO) FOR A METASTATIC BREAST CANCER: FIRST RESULTS OF A PROSPECTIVE OBSERVATIONAL SURVEY ON PRACTICES
Author(s): Lotz JP; Huseini, F ; Finck, M ; Rotarski, M ; Bastit, L ; Riviere, A ; Youssef, A ; Mouysset, J ; Nahon, S ; Biville, F
Conference: 33rd European-Society-for-Medical-Oncology Congress
Location: Stockholm, SWEDEN Date: SEP 12-16, 2008
Sponsor(s): European Soc Med Oncol
Source: ANNALS OF ONCOLOGY Volume: 19 Pages: 73-73 Published: SEP 2008

RARE OVARIAN CANCERS (ROC) IN FRANCE: ANALYSIS OF THE FIRST 100 PATIENTS (PTS) PROSPECTIVELY INCLUDED THROUGH AN ON-LINE OBSERVATORY
Author(s): Ray-Coquard, I ; Guastalla, JP ; Lotz JP ; Weber, B ; Mayeur, D ;Orfeuvre, H ; Provencal, J ; Guar diola, E ; Paraiso, D ; Pujade-Lauraine, E
Conference: 33rd European-Society-for-Medical-Oncology Congress
Location: Stockholm, SWEDEN Date: SEP 12-16, 2008
Sponsor(s): European Soc Med Oncol
Source: ANNALS OF ONCOLOGY Volume: 19 Pages: 211-211 Published: SEP 2008

BREAST CONSERVATION IN THE TREATMENT OF T2 BREAST TUMORS ANALYSIS OF 1988-2003 SEER DATA
Author(s): Rouzier, R.; Lesieur, B.; Gligorov J; et al.
Conference: 31st Annual San Antonio Breast Cancer Symposium
Location: San Antonio, TX Date: DEC 10-14, 2008
Source: CANCER RESEARCH Volume: 69 Issue: 2 Pages: 345S-346S Published: JAN 15 2009

THE EFFICACY AND SAFETY OF NON-PEGYLATED LIPOSOMAL DOXORUBICIN MYOCET AND DOCETAXEL AS FRONT LINE TREATMENT IN HER2-NEU NEGATIVE METASTATIC BREAST CANCER PATIENTS: RESULTS OF A PHASE II TRIAL
Author(s): Cals, L.; Facchini, T.; Dohollou, N.; Gligorov J et al.
Conference: 33rd European-Society-for-Medical-Oncology Congress
Location: Stockholm, SWEDEN Date: SEP 12-16, 2008
Sponsor(s): European Soc Med Oncol
Source: ANNALS OF ONCOLOGY Volume: 19 Pages: 67-67 Published: SEP 2008

CLINICAL IMPACT OF UPFRONT ADJUVANT AROMATASE INHIBITOR (AI) THERAPY
Author(s): Gligorov J; Azria, D.; Namer, M.
Conference: 6th European Breast Cancer Conference
Location: Berlin, GERMANY Date: APR 15-19, 2008
Source: EJC SUPPLEMENTS Volume: 6 Issue: 7 Pages: 120-120 Published: APR 2008